Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 6Breast 6Gynecologic 2CNS 2Sarcoma 1Plasma cell 1Lymphoid 1Head & Neck 1Genitourinary 1Gastrointestinal 1

Conditions

Endometrial Neoplasms 10Ovarian Neoplasms 7Breast Neoplasms 4Neoplasms 2Fallopian Tube Neoplasms 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms by Site 1Neoplasm Metastasis 1Low Grade Serous Ovarian Carcinoma 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Endometrial Endometrioid Adenocarcinoma 1ER+ HER2- Advanced Breast Cancer 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Breast Diseases 1Adenocarcinoma Of Esophagus 1

Interventions

Paclitaxel 28Carboplatin 28pembrolizumab 25Bevacizumab 14liposomal doxorubicin 12Cisplatin 11Gemcitabine 10Radiotherapy 8Drug Therapy 8Cyclophosphamide 8Blood Specimen Collection 8Topotecan 7Nivolumab 7olaparib 6Doxorubicin 6niraparib 5Therapeutics 5Dexamethasone 5pertuzumab 4pazopanib 4lenvatinib 4fludarabine 4cemiplimab 4atezolizumab 4Trastuzumab 4Surveys and Questionnaires 4Psychiatric Rehabilitation 4Polymerase Chain Reaction 4Fulvestrant 4Docetaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × abemaciclib × Gynecologic × Clear all
NCT05768139 2026-05-22

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT03339843 2024-03-15

MiMe-A

Jules Bordet Institute

Phase 2 Completed
85 enrolled
GastrointestinalGenitourinaryGynecologic

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Neoplasms, Urologic Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡